Memphasys launches in vitro utilisation testing of Felix System in China

Grafa01-06

Memphasys (ASX:MEM) has commenced in vitro utilisation testing of its Felix System in China, under an agreement with Heranova Lifesciences HK.

The testing takes place at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, a significant step in validating the Felix System's usability in China's extensive assisted reproductive treatment market.

Heranova will lead the testing, assessing the system's performance across 50 IVF cases.

The evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.

David Ali, Managing Director and CEO of Memphasys, said, "The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater China. This milestone reinforces our commitment to bringing innovative solutions to global markets."

Frank Zhang, Vice President of Medical at Heranova, added, "The Felix System aligns perfectly with our mission to advance reproductive health. This testing will validate its potential to enhance patient outcomes and streamline fertility clinic operations."

China’s IVF market, currently valued at US$5.37 billion ($8.62 billion), is projected to grow significantly by 2030.

Memphasys aims to leverage this growth with the Felix System's advanced capabilities.

At the time of reporting, Memphasys' share price was $0.010.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501475520?lang=en_US&edition=full_marsco","thumbnail":"https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg","is_english":true,"pubTime":"2025-01-06 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501475520","market":null,"top_or_hot":-1,"title":"Memphasys launches in vitro utilisation testing of Felix System in China","media":"Grafa","content":"<img alt=\"\" src=\"https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg\"/><p><a href=\"https://laohu8.com/S/MEM.AU\">Memphasys</a> <a href=\"https://grafa.com/asset/memphasys-ltd-8352-mem.asx\">(ASX:MEM)</a> has commenced in vitro utilisation testing of its Felix System in <a href=\"https://grafa.com/economy/china-cn\">China</a>, under an agreement with Heranova Lifesciences HK.</p>\n<p>The testing takes place at Sichuan Jinxin Xinan Women &amp; Children Hospital in Chengdu, a significant step in validating the Felix System's usability in <a href=\"https://grafa.com/economy/china-cn\">China</a>'s extensive assisted reproductive treatment market.</p>\n<p>Heranova will lead the testing, assessing the system's performance across 50 I<a href=\"https://grafa.com/company/vf-corporation-21296\">VF </a>cases.</p>\n<p>The evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.</p>\n<p>David Ali, Managing Director and CEO of Memphasys, said, \"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater <a href=\"https://grafa.com/economy/china-cn\">China</a>. This milestone reinforces our commitment to bringing innovative solutions to global markets.\"</p>\n<p>Frank Zhang, Vice President of Medical at Heranova, added, \"The Felix System aligns perfectly with our mission to advance reproductive health. This testing will validate its potential to enhance patient outcomes and streamline fertility clinic operations.\"</p>\n<p><a href=\"https://grafa.com/economy/china-cn\">China</a>’s I<a href=\"https://grafa.com/company/vf-corporation-21296\">VF </a>market, currently valued at US$5.37 billion ($8.62 billion), is projected to grow significantly by 2030.</p>\n<p>Memphasys aims to leverage this growth with the Felix System's advanced capabilities.</p>\n<p>At the time of reporting, Memphasys' share price was $0.010.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Memphasys launches in vitro utilisation testing of Felix System in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMemphasys launches in vitro utilisation testing of Felix System in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1019687050\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Grafa </p>\n<p class=\"h-time\">2025-01-06 10:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<img alt=\"\" src=\"https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg\"/><p><a href=\"https://laohu8.com/S/MEM.AU\">Memphasys</a> <a href=\"https://grafa.com/asset/memphasys-ltd-8352-mem.asx\">(ASX:MEM)</a> has commenced in vitro utilisation testing of its Felix System in <a href=\"https://grafa.com/economy/china-cn\">China</a>, under an agreement with Heranova Lifesciences HK.</p>\n<p>The testing takes place at Sichuan Jinxin Xinan Women &amp; Children Hospital in Chengdu, a significant step in validating the Felix System's usability in <a href=\"https://grafa.com/economy/china-cn\">China</a>'s extensive assisted reproductive treatment market.</p>\n<p>Heranova will lead the testing, assessing the system's performance across 50 I<a href=\"https://grafa.com/company/vf-corporation-21296\">VF </a>cases.</p>\n<p>The evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.</p>\n<p>David Ali, Managing Director and CEO of Memphasys, said, \"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater <a href=\"https://grafa.com/economy/china-cn\">China</a>. This milestone reinforces our commitment to bringing innovative solutions to global markets.\"</p>\n<p>Frank Zhang, Vice President of Medical at Heranova, added, \"The Felix System aligns perfectly with our mission to advance reproductive health. This testing will validate its potential to enhance patient outcomes and streamline fertility clinic operations.\"</p>\n<p><a href=\"https://grafa.com/economy/china-cn\">China</a>’s I<a href=\"https://grafa.com/company/vf-corporation-21296\">VF </a>market, currently valued at US$5.37 billion ($8.62 billion), is projected to grow significantly by 2030.</p>\n<p>Memphasys aims to leverage this growth with the Felix System's advanced capabilities.</p>\n<p>At the time of reporting, Memphasys' share price was $0.010.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://grafa.com/news/health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2501475520","we_media_id":"1019687050","thumbnails":["https://images.grafa.com/grafa/media-health-memphasys-launches-in-vitro-utilisation-testing-of-felix-system-in-china-343216-638717262650145372.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501475520","pubTimestamp":1736129465,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Grafa","introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks as well as forex, crypto and economic news. News is generated in near real-time due to Grafa's unique data-led approach to media content generation.","home_visible":1,"id":"1019687050","head_image":"https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15"},"summary":"Memphasys  has commenced in vitro utilisation testing of its Felix System in China, under an agreement with Heranova Lifesciences HK.The testing takes place at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, a significant step in validating the Felix System's usability in China's extensive assisted reproductive treatment market.Heranova will lead the testing, assessing the system's performance across 50 IVF cases.The evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.David Ali, Managing Director and CEO of Memphasys, said, \"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater China. This milestone reinforces our commitment to bringing innovative solutions to global markets.\". Frank Zhang, Vice President of Medical at Heranova, added, \"The Felix System aligns perfectly with our mission to a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Memphasys在中国启动Felix系统的体外利用率测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEM.AU":1},"content_text":"Memphasys (ASX:MEM) has commenced in vitro utilisation testing of its Felix System in China, under an agreement with Heranova Lifesciences HK.\nThe testing takes place at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, a significant step in validating the Felix System's usability in China's extensive assisted reproductive treatment market.\nHeranova will lead the testing, assessing the system's performance across 50 IVF cases.\nThe evaluation covers both the biological performance of improving key sperm parameters and exploring health economic benefits like cost savings and ease of use.\nDavid Ali, Managing Director and CEO of Memphasys, said, \"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix System's presence in Greater China. This milestone reinforces our commitment to bringing innovative solutions to global markets.\"\nFrank Zhang, Vice President of Medical at Heranova, added, \"The Felix System aligns perfectly with our mission to advance reproductive health. This testing will validate its potential to enhance patient outcomes and streamline fertility clinic operations.\"\nChina’s IVF market, currently valued at US$5.37 billion ($8.62 billion), is projected to grow significantly by 2030.\nMemphasys aims to leverage this growth with the Felix System's advanced capabilities.\nAt the time of reporting, Memphasys' share price was $0.010.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501475520"}